ZA911502B - A pharmaceutical solution - Google Patents

A pharmaceutical solution

Info

Publication number
ZA911502B
ZA911502B ZA911502A ZA911502A ZA911502B ZA 911502 B ZA911502 B ZA 911502B ZA 911502 A ZA911502 A ZA 911502A ZA 911502 A ZA911502 A ZA 911502A ZA 911502 B ZA911502 B ZA 911502B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical solution
immusuppreseive
chem
activity
compound
Prior art date
Application number
ZA911502A
Other languages
English (en)
Inventor
Shigeo Nakanishi
Nakanishi Shigeo
Iwao Yamanaka
Yamanaka Iwao
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of ZA911502B publication Critical patent/ZA911502B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
ZA911502A 1990-03-01 1991-02-28 A pharmaceutical solution ZA911502B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP5111090 1990-03-01

Publications (1)

Publication Number Publication Date
ZA911502B true ZA911502B (en) 1991-12-24

Family

ID=12877668

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA911502A ZA911502B (en) 1990-03-01 1991-02-28 A pharmaceutical solution

Country Status (20)

Country Link
EP (1) EP0444659B1 (xx)
JP (1) JP2522121B2 (xx)
KR (1) KR0177158B1 (xx)
CN (1) CN1028961C (xx)
AT (1) ATE143598T1 (xx)
AU (1) AU642707B2 (xx)
CA (1) CA2037408C (xx)
DE (1) DE69122418T2 (xx)
DK (1) DK0444659T3 (xx)
ES (1) ES2093650T3 (xx)
GR (1) GR3021777T3 (xx)
HK (1) HK62797A (xx)
HU (2) HU209436B (xx)
IE (1) IE75221B1 (xx)
MX (1) MX9203032A (xx)
PT (1) PT96916B (xx)
RU (1) RU2028142C1 (xx)
SG (1) SG47986A1 (xx)
UA (1) UA51608C2 (xx)
ZA (1) ZA911502B (xx)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
IE65341B1 (en) * 1990-11-08 1995-10-18 Fujisawa Pharmaceutical Co Suspensions containing tricyclic compounds
US5147877A (en) * 1991-04-18 1992-09-15 Merck & Co. Inc. Semi-synthetic immunosuppressive macrolides
US5565560A (en) * 1991-05-13 1996-10-15 Merck & Co., Inc. O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5162334A (en) * 1991-05-13 1992-11-10 Merck & Co., Inc. Amino O-alkyl, O-alkenyl and O-alkynlmacrolides having immunosuppressive activity
US5189042A (en) * 1991-08-22 1993-02-23 Merck & Co. Inc. Fluoromacrolides having immunosuppressive activity
US5208241A (en) * 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
CA2132636C (en) * 1992-03-30 2002-12-17 Robert P. Waranis Rapamycin formulation for iv injection
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
AT408520B (de) * 1993-05-27 2001-12-27 Novartis Erfind Verwalt Gmbh Galenische formulierungen
US5616588A (en) * 1993-09-30 1997-04-01 American Home Products Corporation Rapamycin formulation for IV injection
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5516770A (en) * 1993-09-30 1996-05-14 American Home Products Corporation Rapamycin formulation for IV injection
IL111004A (en) * 1993-09-30 1998-06-15 American Home Prod Oral formulations of rapamycin
US5693648A (en) * 1994-09-30 1997-12-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity
ZA9710927B (en) * 1996-12-06 1998-06-15 Fujisawa Pharmaceutical Co Pharmaceutical composition.
DK1663217T3 (da) 2003-08-29 2010-11-08 Lifecycle Pharma As Faste dispersioner indeholdende tacrolimus
EP1663216B1 (en) 2003-08-29 2011-11-02 Veloxis Pharmaceuticals A/S Modified release compositions comprising tacrolimus
CN1765365B (zh) * 2004-09-29 2012-01-25 天马药业(集团)股份有限公司 提高苷或苷元类药物在胃内吸收的口服软胶囊
KR100866728B1 (ko) * 2004-11-12 2008-11-03 주식회사종근당 타크로리무스를 함유하는 주사제
FR2879932B1 (fr) * 2004-12-27 2007-03-23 Aventis Pharma Sa Formulations injectable ou administrable par voie orale de derives d'azetidine
CA2688381C (en) 2007-05-30 2016-10-11 Lifecycle Pharma A/S Once daily oral dosage form comprising tacrolimus
CL2008000374A1 (es) 2008-02-05 2008-04-04 Igloo Zone Chile S A Composicion farmaceutica que comprende un polvo para suspension oral de tacrolimus o una de sus sales, hidratos o solvatos y excipientes farmaceuticamente aceptables; procedimiento de preparacion de dicha composicion farmaceutica; y uso para la preve
CN101869547B (zh) 2009-04-24 2012-02-22 张娜 一种他克莫司注射制剂
PT2575769T (pt) 2010-02-17 2016-09-22 Veloxis Pharmaceuticals As Composição de tacrolímus estabilizada
EP4301380A1 (en) 2021-03-03 2024-01-10 Sana Biotechnology, Inc. Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions
CN115463097B (zh) * 2021-06-11 2024-04-19 杭州中美华东制药有限公司 一种他克莫司缓释中间体颗粒的制备工艺

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8430455D0 (en) * 1984-12-03 1985-01-09 Fujisawa Pharmaceutical Co Fr-900506 substance
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
PH26083A (en) * 1987-11-09 1992-02-06 Sandoz Ltd 11, 28-dioxa-4-azatricyclo [22.3.1.04.9) octacos-18-ene derivatives and pharmaceutical compositions containing them and method of use thereof
EP0350164A3 (en) * 1988-06-13 1991-07-24 Beecham Group Plc Amphotericin derivatives

Also Published As

Publication number Publication date
DE69122418D1 (de) 1996-11-07
CA2037408A1 (en) 1991-09-02
AU642707B2 (en) 1993-10-28
HU910681D0 (en) 1991-09-30
SG47986A1 (en) 1998-04-17
EP0444659A3 (en) 1991-12-18
ATE143598T1 (de) 1996-10-15
UA51608C2 (uk) 2002-12-16
KR0177158B1 (ko) 1999-03-20
PT96916B (pt) 1998-07-31
RU2028142C1 (ru) 1995-02-09
HU211502A9 (en) 1995-11-28
HU209436B (en) 1994-06-28
DE69122418T2 (de) 1997-03-06
IE910679A1 (en) 1991-09-11
JPH04211012A (ja) 1992-08-03
ES2093650T3 (es) 1997-01-01
CN1028961C (zh) 1995-06-21
MX9203032A (es) 1992-07-31
GR3021777T3 (en) 1997-02-28
HK62797A (en) 1997-05-16
KR910016336A (ko) 1991-11-05
CA2037408C (en) 2002-12-17
EP0444659A2 (en) 1991-09-04
IE75221B1 (en) 1997-08-27
CN1055110A (zh) 1991-10-09
AU7194991A (en) 1991-10-31
JP2522121B2 (ja) 1996-08-07
PT96916A (pt) 1991-11-29
EP0444659B1 (en) 1996-10-02
DK0444659T3 (da) 1996-11-18
HUT57043A (en) 1991-11-28

Similar Documents

Publication Publication Date Title
EP0444659A3 (en) A pharmaceutical solution
FI914928A (fi) Hydroximetyl (metylencyklopentyl) puriner och -pyrimidiner.
IL148516A (en) Retroviral protease inhibiting compound
ZA927606B (en) Antifungal agent.
SE9100920D0 (sv) New active compounds
IL118367A0 (en) Heteroaroyl derivatives
TW228520B (xx)
DE3876712T2 (de) Antianaerobe naphthyridinverbindungen.
GR3021045T3 (en) 1-Alkyl-2-acyl-1,2-disulfonylhydrazines with antineoplastic activity
ES2093051T3 (es) Purinil- y pirimidil-tetrahidrofuranos.
GR3025084T3 (en) Acrylic derivatives of 2-thiazolypyrroles having a fungicidal activity